Retapamulin: a semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and children.

Abstract

Retapamulin is a semisynthetic pleuromutilin compound with in vitroactivity against Gram-positive bacteria, no cross-resistance to other classes of antimicrobial agents in current use and a low potential for development of resistance. A 1% ointment formulation has been developed for clinical use, and a placebo-controlled trial of impetigo in 210 patients produced significantly higher rates of clinical and microbiological success compared with placebo - 85.6 versus 52.1% and 91.2 versus 50.9%, respectively. Additional comparative studies in over 1900 patients showed noninferiority to topical fusidic acid and oral cephalexin and a low frequency of adverse events. In 2007, retapamulin was approved in the USA for topical treatment of impetigo caused by Streptococcus pyogenes and methicillin-susceptible Staphylococcus aureus, and in the EU for topical treatment of impetigo and infected wounds caused by S. pyogenes and S. aureus, with approvals including adults and children over 9 months of age.

• Authors: Michael R Jacobs
• Journal: Future microbiology (Future Microbiol) Vol. 2 Issue 6 Pg. 591-600 (Dec 2007) ISSN: 1746-0921 [Electronic] England
• PMID: 18041900 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Bridged Bicyclo Compounds, Heterocyclic
• Diterpenes
• Polycyclic Compounds
• pleuromutilin
• retapamulin

Topics

• Administration, Topical
• Adult
• Anti-Bacterial Agents (administration & dosage)
• Bridged Bicyclo Compounds, Heterocyclic (administration & dosage, chemical synthesis, therapeutic use)
• Child
• Child, Preschool
• Diterpenes (chemistry)
• Humans
• Impetigo (drug therapy, microbiology, pathology)
• Infant
• Polycyclic Compounds
• Skin Diseases, Infectious (drug therapy, etiology)
• Staphylococcal Skin Infections (drug therapy, etiology)
• Treatment Outcome